title: Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease.
abstract: The possible role of angiotensin-converting enzyme inhibition in preventing or minimizing tolerance to intravenous nitroglycerin in severe congestive heart failure (CHF) was studied by quantitating the degree of tolerance in 12 patients receiving nitroglycerin (group 1) and in 9 patients (group 2) receiving nitroglycerin and concurrent treatment with captopril (60 +/- 29 mg/day). At peak effect, nitroglycerin produced almost identical hemodynamic changes in both groups, with significant decreases in right atrial and pulmonary arterial wedge pressure, systolic blood pressure and systemic and pulmonary vascular resistances. Cardiac index increased. The extent of nitrate tolerance was calculated for each hemodynamic parameter as the percentage loss of the peak effect achieved by the drug. At 24 hours, 98 +/- 80% of the benefit achieved with respect to right atrial pressure was lost in group 1 and 61 +/- 74% in group 2 (group 1 vs 2, difference not significant). For pulmonary arterial wedge pressure, 51 +/- 31% (group 1) and 85 +/- 53% (group 2) (difference not significant) of the effect was lost, and for cardiac index, 53 +/- 58% (group 1) and 54 +/- 44% (group 2) (difference not significant). Tolerance was also almost identical regarding systolic blood pressure and systemic and pulmonary vascular resistance. Thus, the extent of tolerance to high-dose intravenous nitroglycerin in CHF was unaltered by administration of captopril, indicating that in clinical dosage, counter-regulatory neurohumoral mechanisms involving the renin-angiotensin system appear to be unimportant in its development.
authors.affiliation: Department of Cardiology, Lady Davis Carmel Hospital, Haifa, Israel.
authors.forename: N
authors.initials: N
authors.lastname: Dakak
authors.forename: N
authors.initials: N
authors.lastname: Makhoul
authors.forename: M Y
authors.initials: MY
authors.lastname: Flugelman
authors.forename: A
authors.initials: A
authors.lastname: Merdler
authors.forename: H
authors.initials: H
authors.lastname: Shehadeh
authors.forename: A
authors.initials: A
authors.lastname: Schneeweiss
authors.forename: D A
authors.initials: DA
authors.lastname: Halon
authors.forename: B S
authors.initials: BS
authors.lastname: Lewis
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D002216:Captopril / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications*; D004361:Drug Tolerance; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*; D012083:Renin / Q000097:blood
chemical_list: D000450:Aldosterone; D002216:Captopril; D012083:Renin; D005996:Nitroglycerin